ClinicalTrials.Veeva
Menu

Find clinical trials for Kidney Disease in Detroit, MI

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Kidney Diseases
Chronic Renal Insufficiency
Chronic Kidney Failure
IGA Glomerulonephritis
Renal Insufficiency
Renal Cell Carcinoma
Carcinoma

Kidney Disease trials near Detroit, MI, USA:

A Phase 2 Study of MZE829 in Adults with APOL1 Kidney Disease

This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease...

Enrolling
Proteinuric Kidney Disease
Drug: MZE829

Phase 2

Maze Therapeutics

Shelby Township, Michigan, United States and 21 other locations

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of kidney disease that caus...

Enrolling
Autosomal Dominant Polycystic Kidney Disease
Drug: ABBV-CLS-628
Drug: Placebo

Phase 2

AbbVie
AbbVie

Shelby, Michigan, United States and 14 other locations

is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney...

Enrolling
Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Drug: Tolvaptan (OPC-41061)

Phase 3

Otsuka
Otsuka

Ann Arbor, Michigan, United States and 17 other locations

The purpose of this study is to assess the efficacy and safety of AZD2373 in participants diagnosed with APOL1-Mediated Kidney Disease...

Enrolling
APOL1-Mediated Kidney Disease
Combination Product: Placebo
Device: APOL1 Genotyping Clinical Trial Assay

Phase 2

AstraZeneca
AstraZeneca

Roseville, Michigan, United States and 71 other locations

tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney...

Enrolling
Proteinuric Kidney Disease
Drug: Placebo
Drug: VX-147

Phase 2, Phase 3

Vertex Pharmaceuticals
Vertex Pharmaceuticals

Detroit, Michigan, United States and 325 other locations

Primary Objectives:To evaluate the safety (compared to iron sucrose) and efficacy of ferumoxytol in pediatric CKD subjects with iron deficiency anemi...

Enrolling
Chronic Kidney Disease; Iron Deficiency Anemia
Drug: Iron sucrose
Drug: Ferumoxytol

Phase 3

AMAG Pharmaceuticals
AMAG Pharmaceuticals

Detroit, Michigan, United States and 20 other locations

This study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse. People who have taken a specific t ...

Enrolling
Chronic Kidney Disease
Drug: Placebo matching vicadrostat
Drug: Vicadrostat

Phase 2

Boehringer Ingelheim
Boehringer Ingelheim

Pontiac, Michigan, United States and 146 other locations

We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or wi...

Active, not recruiting
Chronic Kidney Disease
Overweight
Drug: Placebo
Drug: Tirzepatide

Phase 2

Lilly
Lilly

Troy, Michigan, United States and 26 other locations

to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...

Active, not recruiting
Chronic Kidney Disease With High Proteinuria
Drug: Dapagliflozin
Drug: Zibotentan/Dapagliflozin

Phase 3

AstraZeneca
AstraZeneca

Troy, Michigan, United States and 295 other locations

safety, tolerability and the pharmacodynamics (PD) of AZD4144 following oral administration in participants with atherosclerotic cardiovascular disease...

Enrolling
Chronic Kidney Disease
Atherosclerotic Cardiovascular Disease
Drug: AZD4144
Other: Placebo

Phase 1

AstraZeneca
AstraZeneca

Farmington Hills, Michigan, United States and 18 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems